Comparative Pharmacology
Head-to-head clinical analysis: TALWIN 50 versus ULTRAM ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TALWIN 50 versus ULTRAM ER.
TALWIN 50 vs ULTRAM ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pentazocine is a mixed agonist-antagonist opioid analgesic with activity at kappa opioid receptors (agonist) and mu opioid receptors (partial agonist/antagonist). It also exhibits weak antagonistic activity at mu receptors, which reduces abuse liability but may precipitate withdrawal in opioid-dependent patients.
Tramadol is a centrally acting synthetic opioid analgesic that binds to μ-opioid receptors and inhibits serotonin and norepinephrine reuptake.
50 mg orally every 3-4 hours as needed; maximum 600 mg per day.
100 mg orally once daily initially, titrate up to 100 mg twice daily as needed; maximum 200 mg/day.
None Documented
None Documented
Terminal elimination half-life is 2-3 hours. In patients with hepatic impairment, half-life may extend to 5-8 hours; in renal impairment, minimal change, but active metabolite accumulation may occur.
The terminal elimination half-life of tramadol is approximately 6.3 hours (range 5-9 hours), while its active metabolite M1 has a half-life of about 7.4 hours. Clinically, this supports dosing every 24 hours for the extended-release formulation.
Primarily renal (60-70% as unchanged drug and conjugates), with 20-30% biliary/fecal elimination. Approximately 5-10% excreted in feces via bile.
Renal excretion of tramadol and its metabolites accounts for approximately 90% of total elimination. About 10% is excreted unchanged, 30% as O-desmethyltramadol (M1), and the remainder as other minor metabolites. Biliary/fecal excretion is minimal (<10%).
Category C
Category C
Opioid Analgesic
Opioid Analgesic